UNSPSC 51263600: Adrenergic blocking agent quinazolines

This classification denotes adrenergic blocking agents made from benzopyrimidines, or compounds consisting of two six-membered rings, one benzene, one pyrimidine ring.

UNSPSC 51263600 Adrenergic blocking agent quinazolines is a Class code with minimal alignment between its nominal scope and actual recent state and local procurement activity under this designation. The recent opportunities tagged to this code show little relevance to adrenergic blocking agents or quinazoline pharmaceuticals. Seminole County, Florida's IFB for naloxone and drug deactivation systems targets opioid overdose response and harm reduction—a distinct therapeutic category unrelated to adrenergic blockers—while the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescriptions addresses pharmacy benefit program structure and contracting strategy rather than a specific drug class. The code shows no recent activity among state departments, counties, cities, school districts, or transit authorities that actually procures adrenergic blocking agents for formulary inclusion, bulk supply, or clinical use.

The geographic spread covers Florida and Texas based on the two posted opportunities, but these represent exploratory or harm-reduction procurement rather than purchasing driven by the code's nominal therapeutic scope. No representative opportunities in this code reflect genuine demand for adrenergic blocking agent quinazolines from state and local health agencies, corrections departments, or other institutional buyers. The mismatch between code assignment and actual procurement content suggests either miscategorization in the source data or absence of material recent activity in the adrenergic blocking agent market at the state and local level. Vendors pursuing opportunities under this code should verify category alignment with issuing bodies before bid preparation.